A Phase 1/2, Multicenter, Open - label Study of FT - 2102 as a Single Agent and in Combination
with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
Not exact matches
Only a clinical trial that combines
azacitidine with the blinded addition of either vitamin C or a placebo will give the true answer as to whether or not vitamin C increases the efficacy of
azacitidine in patients.
The researchers treated 63 cancer cell lines (26 breast, 14 colorectal and 23 ovarian)
with low - dose 5 -
azacitidine (AZA), an FDA - approved drug for myelodysplastic syndrome, that reverses epigenetic changes by stripping off the methyl group that silences the gene.
A Phase II Trial of Pevonedistat and
Azacitidine in MDS or MDS / MPN Patients Who Fail Primary Therapy
with DNA Methyl Transferase Inhibitors
A combination of the FLT3 kinase inhibitor quizartinib
with 5 -
azacitidine or low - dose cytarabine is active in patients
with FLT3 - ITD mutated myeloid leukemias, according to a new study.
A combination of the FLT3 kinase inhibitor quizartinib
with 5 -
azacitidine (AZA) or low - dose cytarabine (LDAC) is active in patients
with FLT3 - ITD mutated myeloid leukemias, according to a new study.